Calamos Advisors LLC Raises Stake in Harrow, Inc. (NASDAQ:HROW)

Calamos Advisors LLC grew its holdings in Harrow, Inc. (NASDAQ:HROW) by 35.2% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 11,913 shares of the company’s stock after buying an additional 3,103 shares during the period. Calamos Advisors LLC’s holdings in Harrow were worth $400,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in HROW. Quest Partners LLC acquired a new position in Harrow in the 3rd quarter valued at about $29,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Harrow by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock valued at $57,000 after purchasing an additional 227 shares during the period. Hills Bank & Trust Co purchased a new stake in shares of Harrow during the third quarter worth approximately $107,000. Huntington National Bank acquired a new stake in shares of Harrow during the third quarter worth $164,000. Finally, Clarus Group Inc. acquired a new stake in shares of Harrow during the third quarter worth $225,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Stock Performance

Shares of HROW stock opened at $30.89 on Thursday. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. The stock has a 50 day simple moving average of $35.22 and a 200-day simple moving average of $39.64. The company has a market cap of $1.10 billion, a price-to-earnings ratio of -32.86 and a beta of 0.69. Harrow, Inc. has a 12-month low of $9.26 and a 12-month high of $59.23.

Wall Street Analyst Weigh In

Separately, B. Riley dropped their price objective on shares of Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a research note on Wednesday, December 4th.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.